Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

This study has been completed.
Sponsor:
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00168766
First received: September 13, 2005
Last updated: September 12, 2013
Last verified: April 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2008
  Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
No publications provided by Biogen Idec

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):